What is Normunity?
Normunity operates at the vanguard of oncology, focusing on the development of novel anti-cancer therapies that target the complex biology between the immune system and tumor microenvironments. By identifying mechanisms that allow tumors to evade immune surveillance, the company is building a robust pipeline of therapeutic antibodies, bispecific antibodies, and payload-carrying biologics. Its lead program, NRM823, represents a sophisticated T cell engager designed for tumor-specific targeting, positioning the firm as a high-potential player in the next generation of precision immunotherapy.
How much funding has Normunity raised?
Normunity has raised a total of $140M across 2 funding rounds:
Series A
$65M
Series B
$75M
Series A (2022): $65M with participation from Osage University Partners, investorCanaan Ventures, Taiho Ventures, and Sanofi Ventures
Series B (2025): $75M led by Samsara BioCapital, Canaan Partners, Pfizer, Regeneron Ventures, Taiho Ventures, Sanofi Ventures, Enavate Sciences, Connecticut Innovations, Osage Venture Partners, and YK
Key Investors in Normunity
Samsara BioCapital
Samsara BioCapital is a specialized investment firm that partners with scientists and drug developers to create transformative therapeutics, focusing on the next generation of biopharmaceutical breakthroughs.
Pfizer
Pfizer Inc. is a global biopharmaceutical leader dedicated to discovering and delivering innovative medicines and vaccines that address significant health challenges through rigorous scientific research.
Regeneron Ventures
Regeneron Ventures focuses on strategic investments in innovative biotechnology and pharmaceutical companies to support the development of groundbreaking therapies and improve patient outcomes.
What's next for Normunity?
With the successful closure of this Series B round, Normunity is strategically positioned to advance its lead candidate, NRM823, into human clinical trials by 2025. The influx of capital will be directed toward accelerating the development of its broader pipeline and scaling operational capabilities to support the transition into a clinical-stage organization. As the company moves toward its first in-human studies, the focus will remain on validating its unique targeting mechanisms and establishing proof-of-concept in multiple solid tumor indications, a critical step for long-term commercial viability and patient impact.
See full Normunity company page
